For ypTis-3N0M0 rectal cancer patients, Kaplan–Meier analysis demonstrated that patients receiving ACT had comparable 5-year CSS rate as compared to those not receiving ACT in the setting of elevated pretreatment serum CEA levels (76.4 vs 83.5%, P = 0.305) (Figure 2D). This evidence concerns the gene CEACAM5 and rectal cancer.